Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 6/20 | 1.00 |
| ▸ | GSK3B | P49841 | 4/20 | 0.79 |
| ▸ | KIT | P10721 | 2/20 | 0.63 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
| ▸ | JAK3 | P52333 | 8/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 4/20 | 0.53 |
| ▸ | JAK1 | P23458 | 4/20 | 0.53 |
| ▸ | TYK2 | P29597 | 4/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4146895 | 0.88 | AKT2 (1.00) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL24804985 | 0.83 | LCK (0.71) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL2022114 | 0.80 | AKT2 (0.69) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL2048915 | 0.78 | AKT2 (0.70) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL1003408 | 0.78 | AKT2 (1.00) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL2019251 | 0.78 | AKT2 (0.83) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL30673936 | 0.78 | AKT2 (1.00) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL2022699 | 0.78 | AKT2 (0.78) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL3918663 | 0.77 | AKT2 (0.62) | AKT2GSK3BLCKJAK3JAK2 | |
| SCHEMBL2019457 | 0.77 | LCK (1.00) | AKT2GSK3BKITLCKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| CN-101484173-A | Pharmaceutical combinations of pk inhibitors and other active agents | ASTEX THERAPEUTICS LTD (GB) | 2009-07-15 | — | — | CN | disclosed |
| CN-101479263-A | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD (GB) | 2009-07-08 | — | — | CN | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090082370-A1 | Pharmaceutical Combinations of PK Inhibitors and Other Active Agents | ASTEX THERAPEUTICS LIMITED (GB) | 2009-03-26 | — | — | US | disclosed |
| EP-2037931-A2 | PHARMACEUTICAL COMBINATIONS OF PK INHIBITORS AND OTHER ACTIVE AGENTS | Astex Therapeutics Limited (GB) | 2009-03-25 | — | — | EP | disclosed |
| EP-2016077-A2 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007125315-A2 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125315-A2 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125310-A2 | PHARMACEUTICAL COMBINATIONS OF PK INHIBITORS AND OTHER ACTIVE AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| EP-1812003-A1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006046023-A1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253718-A1 | Pharmaceutical Compounds | GRK3, CNKSR1, CSNK1G3 | AKT2 153/4885GSK3B 157/4885KIT 2866/4885 |
| US-20090082370-A1 | Pharmaceutical Combinations of PK Inhibitors and Other Active Agents | PKN2, PKN1, PKN3 | AKT2 523/4885GSK3B 109/4885KIT 2305/4885 |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | OXSR1, CDK1, CDK3 | AKT2 999/4885GSK3B 605/4885KIT 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.